Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 15/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25109993 | 0.80 | PRMT5 (0.39) | PRMT5WDR77 | |
| SCHEMBL20733594 | 0.74 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL20721553 | 0.74 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL4430217 | 0.73 | ADORA2A (0.55) | PRMT5WDR77 | |
| SCHEMBL1738408 | 0.73 | ADORA2A (0.55) | PRMT5WDR77 | |
| SCHEMBL13598781 | 0.73 | ADORA2A (0.55) | PRMT5WDR77 | |
| SCHEMBL23535874 | 0.73 | PRMT5 (0.60) | PRMT5WDR77 | |
| SCHEMBL13598733 | 0.73 | ADORA2A (0.55) | PRMT5WDR77 | |
| SCHEMBL31123838 | 0.73 | PRMT5 (0.60) | PRMT5WDR77 | |
| SCHEMBL18661710 | 0.72 | ADORA2A (0.42) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11078205-B2 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3665179-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-05-14 | — | — | US | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078205-B2 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 142/4885 |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.